Company Filing History:
Years Active: 1998-2010
Title: Tze-Ming Chan: Innovator in Chemokine Receptor Inhibition
Introduction
Tze-Ming Chan is a notable inventor based in Bridgewater, NJ (US). He has made significant contributions to the field of pharmaceutical chemistry, particularly in the development of compounds that inhibit chemokine receptors. With a total of 4 patents to his name, Chan's work has the potential to impact various medical treatments.
Latest Patents
Chan's latest patents include innovative compounds such as piperidinyl piperidine derivatives and piperidinyl piperazine derivatives. These compounds are designed to act as inhibitors of the CCR5 receptors, which play a crucial role in various diseases. The patents detail methods for preparing these compounds, pharmaceutical compositions containing them, and their applications in treating conditions such as Human Immunodeficiency Virus (HIV), solid organ transplant rejection, and multiple sclerosis.
Career Highlights
Tze-Ming Chan is currently associated with Schering Corporation, where he continues to advance his research in pharmaceutical innovations. His work focuses on developing new therapeutic agents that can provide effective treatments for complex diseases.
Collaborations
Chan has collaborated with notable colleagues, including Wenqing Feng and Michael W Miller, to further enhance the scope and impact of his research. These collaborations have contributed to the successful development of his patented compounds.
Conclusion
Tze-Ming Chan's innovative work in the field of chemokine receptor inhibition showcases his dedication to advancing medical science. His contributions have the potential to lead to significant improvements in the treatment of various diseases.